Vanda Wins Denial of Petition For Rehearing on Fanapt®

WASHINGTON , Aug. 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit denied petitions for panel rehearing and rehearing en banc filed by West-Ward Pharmaceuticals , a subsidiary of Hikma Pharmaceuticals , relating to Vanda's U.S. Patent number 8,586,610 (the '610 Patent) for Fanapt®. This denial by U.S. Court of Appeals for the Federal Circuit leaves undisturbed its prior decision that West-Ward Pharmaceuticals's Abbreviated New Drug Application for iloperidone infringed the '610 Patent, and that West-Ward Pharmaceuticals had not proven the '610 Patent invalid. The '610 Patent is set to expire November 2, 2027 . About Vanda Pharmaceuticals Inc. Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc. , please visit www.vandapharma.com . About Fanapt® For full U.S. Prescribing Information for Fanapt®, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com . Investor Contact: Jim Kelly Executive Vice President & Chief Financial Officer Vanda Pharmaceuticals Inc. (202) 734-3428 [email protected] View original content: http://www.prnewswire.com/news-releases/vanda-wins-denial-of-petition-for-rehearing-on-fanapt-300697128.html SOURCE Vanda Pharmaceuticals Inc. Investor Relations IR Home Stock Information Stock Quote Stock Chart SEC Filings Analyst Coverage Corporate Governance Highlights Management Board of Directors Committee Composition Guidelines VandaHotline Information Request E-mail Alerts Tools Print Page E-mail Page

The release as fetched from its publisher. vandapharma.com ↗